1
|
Ma JT, Xia S, Zhang BK, Luo F, Guo L, Yang Y, Gong H, Yan M. The pharmacology and mechanisms of traditional Chinese medicine in promoting liver regeneration: A new therapeutic option. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2023; 116:154893. [PMID: 37236047 DOI: 10.1016/j.phymed.2023.154893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 05/04/2023] [Accepted: 05/17/2023] [Indexed: 05/28/2023]
Abstract
BACKGROUND The liver is renowned for its remarkable regenerative capacity to restore its structure, size and function after various types of liver injury. However, in patients with end-stage liver disease, the regenerative capacity is inhibited and liver transplantation is the only option. Considering the limitations of liver transplantation, promoting liver regeneration is suggested as a new therapeutic strategy for liver disease. Traditional Chinese medicine (TCM) has a long history of preventing and treating various liver diseases, and some of them have been proven to be effective in promoting liver regeneration, suggesting the therapeutic potential in liver diseases. PURPOSE This review aims to summarize the molecular mechanisms of liver regeneration and the pro-regenerative activity and mechanism of TCM formulas, extracts and active ingredients. METHODS We conducted a systematic search in PubMed, Web of Science and the Cochrane Library databases using "TCM", "liver regeneration" or their synonyms as keywords, and classified and summarized the retrieved literature. The PRISMA guidelines were followed. RESULTS Forty-one research articles met the themes of this review and previous critical studies were also reviewed to provide essential background information. Current evidences indicate that various TCM formulas, extracts and active ingredients have the effect on stimulating liver regeneration through modulating JAK/STAT, Hippo, PI3K/Akt and other signaling pathways. Besides, the mechanisms of liver regeneration, the limitation of existing studies and the application prospect of TCM to promote liver regeneration are also outlined and discussed in this review. CONCLUSION This review supports TCM as new potential therapeutic options for promoting liver regeneration and repair of the failing liver, although extensive pharmacokinetic and toxicological studies, as well as elaborate clinical trials, are still needed to demonstrate safety and efficacy.
Collapse
Affiliation(s)
- Jia-Ting Ma
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China
| | - Shuang Xia
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China
| | - Bi-Kui Zhang
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China
| | - Fen Luo
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China
| | - Lin Guo
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China
| | - Yan Yang
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China
| | - Hui Gong
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China.
| | - Miao Yan
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China; Institute of Clinical Pharmacy, Central South University, Changsha, China; International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China.
| |
Collapse
|
2
|
Dai L, Gao X, Ye Z, Li H, Yao X, Lu D, Wu N. The "Traditional Chinese medicine regulating liver regeneration" treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data. Front Med 2021; 15:495-505. [PMID: 33433899 PMCID: PMC7801774 DOI: 10.1007/s11684-020-0790-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Accepted: 04/17/2020] [Indexed: 12/04/2022]
Abstract
On the basis of real-world clinical data, the study aimed to explore the effect and mechanisms of the treatment plan of “traditional Chinese medicine (TCM) regulating liver regeneration.” A total of 457 patients with HBV-related liver failure were retrospectively collected. The patients were divided into three groups: the modern medicine control group (MMC group), patients treated with routine medical treatment; the control group combining traditional Chinese and Western medicine (CTW), patients treated with routine medical treatment plus the common TCM formula; and the treatment group of “TCM regulating liver regeneration” (RLR), patients treated with both routine medical treatment and the special TCM formula of RLR. After 8 weeks of treatment, the mortality of patients in the RLR group (12.31%) was significantly lower than those in the MMC (50%) and CTW (29.11%) groups. Total bilirubin level significantly decreased and albumin increased in the RLR group when compared with the MMC and CTW groups (P < 0.05). In addition, there were significant differences in the expression of several cytokines related to liver regeneration in the RLR group compared with the MMC group. RLR treatment can decrease jaundice, improve liver function, and significantly reduce the mortality in patients with HBV-related liver failure. The mechanism may be related to the role of RLR treatment in influencing cytokines related to liver regeneration.
Collapse
Affiliation(s)
- Ling Dai
- Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China.,Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan, 430074, China.,Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan, 430061, China
| | - Xiang Gao
- Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China.,Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan, 430074, China.,Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan, 430061, China
| | - Zhihua Ye
- Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China.,Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan, 430074, China.,Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan, 430061, China
| | - Hanmin Li
- Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China. .,Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China. .,Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan, 430074, China. .,Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan, 430061, China.
| | - Xin Yao
- Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China.,Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan, 430074, China.,Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan, 430061, China
| | - Dingbo Lu
- Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China.,Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan, 430074, China.,Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan, 430061, China
| | - Na Wu
- Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.,Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430074, China.,Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan, 430074, China.,Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan, 430061, China
| |
Collapse
|
3
|
Li H, Wu R, Yu H, Zheng Q, Chen Y. Bioactive Herbal Extracts of Traditional Chinese Medicine Applied with the Biomaterials: For the Current Applications and Advances in the Musculoskeletal System. Front Pharmacol 2021; 12:778041. [PMID: 34776987 PMCID: PMC8581265 DOI: 10.3389/fphar.2021.778041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 10/15/2021] [Indexed: 02/05/2023] Open
Abstract
Traditional Chinese medicine (TCM) has demonstrated superior therapeutic effect for musculoskeletal diseases for thousands of years. Recently, the herbal extracts of TCM have received rapid advances in musculoskeletal tissue engineering (MTE). A literature review collecting both English and Chinese references on bioactive herbal extracts of TCM in biomaterial-based approaches was performed. This review provides an up-to-date overview of application of TCMs in the field of MTE, involving regulation of multiple signaling pathways in osteogenesis, angiogenesis, anti-inflammation, and chondrogenesis. Meanwhile, we highlight the potential advantages of TCM, opening the possibility of its extensive application in MTE. Overall, the superiority of traditional Chinese medicine turns it into an attractive candidate for coupling with advanced additive manufacturing technology.
Collapse
Affiliation(s)
- Haotao Li
- Department of Orthopedics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- Shantou University Medical College, Shantou, China
| | - Rongjie Wu
- Department of Orthopedics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- Shantou University Medical College, Shantou, China
| | - Haiyang Yu
- Department of Orthopedics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Qiujian Zheng
- Department of Orthopedics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- *Correspondence: Qiujian Zheng, ; Yuanfeng Chen,
| | - Yuanfeng Chen
- Department of Orthopedics, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- Research Department of Medical Science, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
- *Correspondence: Qiujian Zheng, ; Yuanfeng Chen,
| |
Collapse
|
4
|
Chang M, Wu M, Li H. Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice. Drug Deliv 2019; 25:1984-1995. [PMID: 30499350 PMCID: PMC6282420 DOI: 10.1080/10717544.2018.1526227] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
At present, the chemotherapy of advanced inoperable liver cancer is limited with serious side effects. Curcumin possesses multiple cancer preventive activities and low safety concerns. However, its poor solubility and instability in water pose significant pharmacological barriers to its clinical application. In this study, we presented a novel delivery system – the glycyrrhetinic acid modified curcumin-loaded cationic liposomes (GAMCLCL) and investigated its antitumor activities on HepG2 cells in vitro and in H22 tumor-bearing mice. The experimental results demonstrated that GAMCLCL was a cationic liposome and could be Intravenous administration. Compared to free curcumin, GAMCLCL exhibited stronger antitumor activities in vitro and in vivo. The antitumor results of GAMCLCL after intravenous administration were very similar to those after intratumoral administration. The main activities of GAMCLCL and curcumin included inhibition of HepG2 cell proliferation, inhibition of tumor growth, reduction of tumor microvascular density, down-regulation of the expression of VEGF protein, and up-regulation of the expression of Caspases3 protein in H22 tumor tissues. Furthermore, GAMCLCL improved the parameters of WBC, RBC, ALT, CRE, LDH of H22 tumor-bearing mice. Curcumin is a nontoxic natural compound with definite antitumor activities, its antitumor effects can be enhanced by preparation of GAMCLCL.
Collapse
Affiliation(s)
- Mingxiang Chang
- a First clinical medical school , Hubei University of Chinese Medicine , Wuhan , P.R. China.,b Hubei Provincial Hospital of Traditional Chinese Medicine , Wuhan , P.R. China.,c Hubei Province Academy of Traditional Chinese Medicine , Wuhan , P.R.China
| | - Meimei Wu
- b Hubei Provincial Hospital of Traditional Chinese Medicine , Wuhan , P.R. China.,c Hubei Province Academy of Traditional Chinese Medicine , Wuhan , P.R.China
| | - Hanmin Li
- b Hubei Provincial Hospital of Traditional Chinese Medicine , Wuhan , P.R. China.,c Hubei Province Academy of Traditional Chinese Medicine , Wuhan , P.R.China
| |
Collapse
|
5
|
Feng Y, Yin Z, Zhang D, Srivastava A, Ling C. Chinese Medicine Protein and Peptide in Gene and Cell Therapy. Curr Protein Pept Sci 2018; 20:251-264. [PMID: 29895243 DOI: 10.2174/1389203719666180612082432] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2018] [Revised: 04/10/2018] [Accepted: 05/22/2018] [Indexed: 01/05/2023]
Abstract
The success of gene and cell therapy in clinic during the past two decades as well as our expanding ability to manipulate these biomaterials are leading to new therapeutic options for a wide range of inherited and acquired diseases. Combining conventional therapies with this emerging field is a promising strategy to treat those previously-thought untreatable diseases. Traditional Chinese medicine (TCM) has evolved for thousands of years in China and still plays an important role in human health. As part of the active ingredients of TCM, proteins and peptides have attracted long-term enthusiasm of researchers. More recently, they have been utilized in gene and cell therapy, resulting in promising novel strategies to treat both cancer and non-cancer diseases. This manuscript presents a critical review on this field, accompanied with perspectives on the challenges and new directions for future research in this emerging frontier.
Collapse
Affiliation(s)
- Yinlu Feng
- Department of Traditional Chinese Medicine, 401 Hospital of the Chinese People's Liberation Army, Qingdao, Shandong 266071, China.,Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Zifei Yin
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Daniel Zhang
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Arun Srivastava
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| | - Chen Ling
- Division of Cellular and Molecular Therapy, Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32611, FL, United States
| |
Collapse
|
6
|
Li H, Ye Z, Gao X, Zhang L, Yao X, Gu J, Lu D, Wan M, Xiao L, Cai W, Yan X, Zhao B, Wu Y, Zhang J. Diwu Yanggan capsule improving liver histological response for patients with HBeAg-negative chronic hepatitis B: a randomized controlled clinical trial. Am J Transl Res 2018; 10:1511-1521. [PMID: 29887964 PMCID: PMC5992542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 02/27/2018] [Indexed: 06/08/2023]
Abstract
The number of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) has shown a significant upward trend in recent years. However, antiviral drugs are not very effective. Regulation of liver regeneration by traditional Chinese medicine is an important way to improve clinical efficacy. This randomized controlled trial assessed the efficacy and safety of DWYG in patients with HBeAg-negative CHB. Overall, 130 subjects were randomized to (A) DWYG 1.2 g three times daily (n = 44), (B) entecavir 0.5 mg/day (n = 43) in combination with DWYG or (C) entecavir 0.5 mg/day (n = 43). The liver histological response rate was assessed as the primary efficacy endpoint. The results showed that the liver histological response rate in the combination treatment group was significantly higher than that in the group with entecavir (71.43% versus 22.22%; P = 0.036) after 48 weeks of treatment. And the pathological progression rate of liver in the group with DWYG was significantly lower than that of the entecavir group during 228 weeks of follow-up (0% versus 60.00%; P = 0.019). No significant adverse events occurred during the study. In conclusion, treating HBeAg-negative CHB with DWYG is safe and effective to improve liver histological response.
Collapse
Affiliation(s)
- Hanmin Li
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Zhihua Ye
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Xiang Gao
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Lisheng Zhang
- College of Veterinary Medicine, Huazhong Agricultural UniversityWuhan 430070, Hubei Province, China
| | - Xin Yao
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Jianxun Gu
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Dingbo Lu
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Ming Wan
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Lin Xiao
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Wangxi Cai
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Xuesheng Yan
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Binbin Zhao
- Basic Medical College, Hubei University of Chinese MedicineWuhan 430065, Hubei Province, China
| | - Yu Wu
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| | - Jinrong Zhang
- Hubei Provincial Hospital of Traditional Chinese MedicineWuhan 430061, Hubei Province, China
- Hubei Province Academy of Traditional Chinese MedicineWuhan 430074, Hubei Province, China
| |
Collapse
|
7
|
Chinese Herbal Medicine as an Adjunctive Therapy Ameliorated the Incidence of Chronic Hepatitis in Patients with Breast Cancer: A Nationwide Population-Based Cohort Study. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2017; 2017:1052976. [PMID: 29234362 PMCID: PMC5682887 DOI: 10.1155/2017/1052976] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/24/2017] [Accepted: 09/12/2017] [Indexed: 11/23/2022]
Abstract
We conducted a National Health Insurance Research Database-based Taiwanese nationwide population-based cohort study to evaluate whether Chinese herbal medicine (CHM) treatment decreased the incidence of chronic hepatitis in breast cancer patients receiving chemotherapy and/or radiotherapy. A total of 81171 patients were diagnosed with breast cancer within the defined study period. After randomly equal matching, data from 13856 patients were analyzed. Hazard ratios of incidence rate of chronic hepatitis were used to determine the influence and therapeutic potential of CHM in patients with breast cancer. The patients with breast cancer receiving CHM treatment exhibited a significantly decreased incidence rate of chronic hepatitis even across the stratification of age, CCI score, and treatments. The cumulative incidence of chronic hepatitis for a period of seven years after initial breast cancer diagnosis was also reduced in the patients receiving CHM treatment. The ten most commonly used single herbs and formulas were effective in protecting liver function in patients with breast cancer, where Hedyotis diffusa and Jia-Wei-Xiao-Yao-San were the most commonly used herbal agents. In conclusion, our study provided information that western medicine therapy combined with CHM as an adjuvant modality may have a significant impact on liver protection in patients with breast cancer.
Collapse
|
8
|
Zhang Y, Mao X, Su J, Geng Y, Guo R, Tang S, Li J, Xiao X, Xu H, Yang H. A network pharmacology-based strategy deciphers the underlying molecular mechanisms of Qixuehe Capsule in the treatment of menstrual disorders. Chin Med 2017; 12:23. [PMID: 28835770 PMCID: PMC5563918 DOI: 10.1186/s13020-017-0145-x] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Accepted: 08/16/2017] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND QiXueHe Capsule (QXHC) is a Chinese patent drug that is extensively used for the treatment of menstrual disorders. However, its underlying pharmacological mechanisms have not been fully elucidated. METHODS A list of QXHC putative targets were predicted using MetaDrug. An interaction network using links between QXHC putative targets and the known therapeutic targets of menstrual disorders was constructed. QXHC candidate targets were also identified via calculating the topological feature values of nodes in the network. Additionally, molecular docking simulation was performed to determine the binding efficiency of QXHC compound-putative target pairs. RESULTS A total of 1022 putative targets were predicted for 311 chemical components containing in QXHC. Following the calculation of topological features of QXHC putative target-known therapeutic target of menstrual disorder network, 66 QXHC candidate targets for the treatment of menstrual disorders were identified. Functionally, QXHC candidate targets were significantly associated with several biological pathways, such as VEGF and Chemokine signaling pathways, Alanine/aspartate/glutamate metabolism, Long-term depression and T/B cell receptor signaling pathway. Moreover, molecular docking simulation demonstrated that there were 20 pairs of QXHC chemical component-candidate target had the strong binding free energy. CONCLUSIONS This novel and scientific network pharmacology-based study holistically deciphers that the pharmacological mechanisms of QXHC in the treatment of menstrual disorders may be associated with its involvement into hemopoiesis, analgesia, nutrients absorption and metabolism, mood regulation, as well as immune modulation.
Collapse
Affiliation(s)
- Yanqiong Zhang
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing, 100700 China
| | - Xia Mao
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing, 100700 China
| | - Jing Su
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing, 100700 China
| | - Ya Geng
- School of Basic Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250300 China
| | - Rui Guo
- College of Pharmacy, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193 China
| | - Shihuan Tang
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing, 100700 China
| | - Junfang Li
- College of Pharmacy, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193 China
| | - Xuefeng Xiao
- College of Pharmacy, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193 China
| | - Haiyu Xu
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing, 100700 China
| | - Hongjun Yang
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, No. 16, Nanxiaojie, Dongzhimennei, Beijing, 100700 China
| |
Collapse
|
9
|
Abstract
中医药调控肝再生是防治肝病及其相关病证的重要策略, 已形成的研究热点方兴未艾. 近些年来取得的主要进展至少包括以下几个方面: 调控肝损伤与肝再生失衡提高了中医/中西医结合防治肝病及其相关病证的临床疗效, "髓"为中心治疗靶点的研究进展揭示了中医/中西医结合防治肝病及其相关病证的疗效机制, 整体动态微调早调的作用方式满足了肝再生调控复杂多变的需要, 解决了单靶点调控肝再生疗效有限的关键科学问题, 平衡协调的疗效考核与结局指标的综合判断为中医药调控肝再生的临床推广应用提供了途径和方法.
Collapse
|
10
|
Abstract
This paper aims to review the progress and problems in research of liver regeneration regulation in recent years and to explore the solutions to these problems by performing a systematic literature review combined with the author's work. In recent years, great progress has been made in preventing and treating liver diseases by regulating liver regeneration, for example, the coordination of promotion and inhibition, the reverse inhibition and positive induction, slight adjustment and preconditioning, and overall dynamic control. Current key scientific problems in this field include distinguishing between abnormal and normal liver regeneration, mechanisms underlying their mutual transformation, objective criteria for clinical application, and quantitative indicators for judging the efficacy. The regulation of liver regeneration for preventing and treating liver diseases has become a hot research topic, and the clinical translation and application of studies remain to be promoted on the basis of further in-depth research.
Collapse
|